Menu
Afatinib dimaleate is a medication that belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). It is primarily used for the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC) that harbors specific mutations in the epidermal growth factor receptor (EGFR) gene.
Afatinib works by inhibiting multiple members of the EGFR family of proteins, which are involved in promoting cell growth and survival. In cancers with EGFR mutations, these proteins can become hyperactive, leading to uncontrolled cell division and tumor growth. Afatinib helps to block the signals that these mutated receptors send, thereby slowing down or inhibiting the growth of cancer cells.
It is approved for the treatment of EGFR mutation-positive NSCLC, both as initial therapy (first-line treatment) and as a later-line treatment for patients who have progressed on other EGFR-targeted therapies.
Common side effects of afatinib may include diarrhea, rash, fatigue, decreased appetite, and nail changes. These side effects are often manageable with appropriate medical care.
It’s important to note that while afatinib has demonstrated efficacy in specific types of cancer, its use should be determined by a medical oncologist based on the individual patient’s condition, genetic profile, and treatment history. Additionally, treatment guidelines and available medications may have evolved since my last knowledge update in September 2021, so it’s advisable to consult with a healthcare professional or refer to more recent sources for the latest information on afatinib dimaleate.
Alectinib is a targeted therapy used for the treatment of specific types of cancer, particularly non-small cell lung cancer (NSCLC) that harbors certain genetic mutations.
Alectinib is primarily used to treat NSCLC cases where the cancer cells have a rearrangement of the anaplastic lymphoma kinase (ALK) gene. This genetic alteration results in the production of an abnormal ALK protein that drives the growth of cancer cells. Alectinib belongs to a class of drugs called ALK inhibitors, which specifically target and block the activity of this abnormal ALK protein.
By inhibiting the activity of the abnormal ALK protein, alectinib helps to slow down or stop the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Alectinib is typically used for patients with ALK-positive NSCLC who have either not responded to other treatments or who have experienced disease progression after initial therapy. It is available in oral capsule form and is usually taken once or twice daily.
Common side effects of alectinib may include fatigue, constipation, swelling, muscle or joint pain, and changes in liver function tests. As with any medication, it’s important for patients to communicate with their healthcare provider about any side effects or concerns they may have.
It’s worth noting that medical knowledge and treatment options can evolve, and new developments may have occurred since my last knowledge update in September 2021. Therefore, I recommend consulting with a healthcare professional or referring to more recent sources for the latest information on alectinib and its use in cancer treatment.
Alpelisib is a targeted therapy used for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is specifically approved for use in combination with fulvestrant, another medication used in the treatment of HR+ breast cancer.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor. The PI3K pathway is a signaling pathway that plays a crucial role in regulating cell growth, survival, and metabolism. Mutations or dysregulation of the PI3K pathway can contribute to the growth and spread of cancer cells. Alpelisib targets a specific mutation in the PIK3CA gene, which is commonly found in HR+ breast cancer.
By inhibiting the PI3K pathway, alpelisib helps to slow down the progression of cancer cells and improves the effectiveness of hormone-based treatments like fulvestrant.
Alpelisib is usually prescribed to patients who have already received endocrine therapy (hormone-based therapy) and have progressed on such treatments. It’s important to note that alpelisib is generally used in cases where the PIK3CA mutation is present in the tumor.
Common side effects of alpelisib may include hyperglycemia (high blood sugar), rash, diarrhea, nausea, and fatigue. It’s important for patients to work closely with their healthcare provider and discuss any side effects or concerns they may have while taking alpelisib.
As medical knowledge and treatments can evolve, it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on alpelisib and its use in breast cancer treatment.
Avapritinib (brand name: Ayvakit) is a targeted therapy medication used for the treatment of certain types of cancer, specifically gastrointestinal stromal tumors (GISTs) that have specific mutations.
Gastrointestinal stromal tumors (GISTs) are rare but often treatable tumors that can develop in the stomach or other parts of the gastrointestinal tract. A significant subset of GISTs carry mutations in the KIT or PDGFRA genes, which lead to the activation of signaling pathways promoting tumor growth.
Avapritinib is a tyrosine kinase inhibitor (TKI) that targets these specific mutations in KIT and PDGFRA genes. By inhibiting the activity of the mutant proteins, avapritinib helps to slow down or stop the growth of GISTs and can lead to tumor shrinkage and improved patient outcomes.
Avapritinib is indicated for:
The approval of avapritinib has provided a treatment option for patients with GISTs who have mutations that are not effectively targeted by other available therapies.
Common side effects of avapritinib may include edema (fluid retention), nausea, fatigue, cognitive impairment, muscle and joint pain, and abdominal pain.
As with any medication, it’s important for patients to work closely with their healthcare provider and discuss any potential side effects or concerns they may have while taking avapritinib. As medical knowledge and treatments can evolve, it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on avapritinib and its use in GIST treatment.
As of my last knowledge update in September 2021, bemcentinib is an investigational drug that belongs to a class of medications called AXL inhibitors. It is being developed for the treatment of various types of cancer and other diseases.
AXL is a protein receptor that plays a role in promoting cell survival, growth, and invasion. In cancer, overexpression of AXL has been associated with tumor progression, metastasis, and resistance to certain treatments.
Bemcentinib works by inhibiting the activity of AXL, which could potentially slow down the growth and spread of cancer cells. It is being studied in clinical trials as a targeted therapy for various types of cancer, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and other solid tumors.
Clinical trials are essential for determining the safety, effectiveness, and optimal dosing of new medications like bemcentinib. These trials help researchers understand how the drug interacts with the body, its potential benefits, and any potential side effects.
Since my information might be outdated, I recommend checking with more recent sources such as clinical trial databases, medical journals, or your healthcare provider for the latest information on bemcentinib and its development as a treatment for cancer or other diseases.
Bevacizumab (brand name: Avastin) is a targeted therapy medication used in the treatment of various types of cancer. It is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein that plays a critical role in promoting the growth of new blood vessels, a process known as angiogenesis. In cancer, angiogenesis is important for tumor growth and metastasis.
Bevacizumab works by binding to and inhibiting the activity of VEGF. By doing so, it helps to block the formation of new blood vessels that supply nutrients and oxygen to cancer cells, ultimately slowing down tumor growth and potentially preventing its spread.
Bevacizumab has been approved for use in several cancer types, including:
Bevacizumab is typically administered intravenously. Common side effects may include high blood pressure, bleeding, proteinuria (excess protein in the urine), and increased risk of wound healing complications. The risks and benefits of bevacizumab treatment should be carefully considered in consultation with a healthcare provider.
It’s important to note that my knowledge is based on information available up until September 2021, and there may have been developments or changes since then. Always consult with a healthcare professional or refer to more recent sources for the latest information on bevacizumab and its use in cancer treatment.
Binimetinib (brand name: Mektovi) is a targeted therapy medication used for the treatment of certain types of cancer, particularly advanced or metastatic melanoma.
Binimetinib is classified as a mitogen-activated protein kinase (MEK) inhibitor. The MEK pathway is involved in cell signaling that regulates cell growth, survival, and proliferation. In some cancers, mutations in the pathway can lead to uncontrolled cell growth and tumor progression.
Binimetinib works by specifically inhibiting the activity of the MEK protein, which is part of the MEK pathway. By blocking this pathway, binimetinib helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Binimetinib is often used in combination with other targeted therapies, such as encorafenib (a BRAF inhibitor), for the treatment of advanced melanoma with specific genetic mutations, such as BRAF V600E or V600K mutations.
Common side effects of binimetinib may include fatigue, rash, nausea, diarrhea, increased blood creatine kinase levels, and edema (fluid retention).
As medical knowledge and treatments can evolve, it’s important to consult with a healthcare professional or refer to more recent sources for the latest information on binimetinib and its use in cancer treatment.
Bosutinib (brand name: Bosulif) is a medication used in the treatment of certain types of cancer, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Bosutinib is classified as a tyrosine kinase inhibitor (TKI). It works by targeting and inhibiting specific tyrosine kinases, including the BCR-ABL1 fusion protein, which is characteristic of CML and Ph+ ALL. The BCR-ABL1 fusion protein drives the uncontrolled growth of cancer cells. By inhibiting this protein, bosutinib helps to slow down or halt the growth of cancer cells, leading to improved patient outcomes.
Bosutinib is indicated for the following:
Common side effects of bosutinib may include diarrhea, nausea, abdominal pain, rash, and low blood cell counts (anemia, neutropenia, and thrombocytopenia). Like all medications, bosutinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
As with any medical treatment, it’s important to stay informed about the latest developments and to consult with a healthcare professional or refer to more recent sources for the most up-to-date information on bosutinib and its use in cancer treatment.
Carboplatin and paclitaxel (often referred to as “Carboplatin-Taxol”) are commonly used chemotherapy drugs that are often administered together as a combination therapy for the treatment of various types of cancer, including ovarian cancer, lung cancer, and some types of breast cancer.
Here’s a brief overview of each drug and their use:
The combination of carboplatin and paclitaxel is a well-established treatment regimen for certain cancers. It is often used in ovarian cancer as a first-line treatment and may also be used in lung cancer and other malignancies. The specific dosing, timing, and duration of treatment depend on the type and stage of cancer, as well as the patient’s overall health and individual treatment plan.
As with any chemotherapy regimen, the combination of carboplatin and paclitaxel can have potential side effects, including hair loss, nausea, vomiting, fatigue, decreased blood cell counts, and nerve damage (neuropathy). These side effects should be discussed with a healthcare provider, and patients should be closely monitored during treatment.
It’s important to consult with a healthcare professional or oncologist for personalized information and guidance if you or a loved one are considering or undergoing treatment with carboplatin and paclitaxel or any other chemotherapy regimen.
Cemiplimab-rwlc (brand name: Libtayo) is a medication used in cancer immunotherapy for the treatment of certain types of cancer. It is a monoclonal antibody that targets a protein called programmed death receptor-1 (PD-1), which plays a role in regulating the immune response.
Cemiplimab is indicated for the treatment of:
Cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This helps to unleash the immune system to recognize and attack cancer cells, leading to enhanced anti-tumor immune responses.
Common side effects of cemiplimab-rwlc may include fatigue, rash, diarrhea, nausea, and decreased appetite. Like other immunotherapies, it can also lead to immune-related side effects such as pneumonitis, colitis, and thyroid disorders.
As medical knowledge and treatments can evolve, it’s important to consult with a healthcare professional or refer to more recent sources for the latest information on cemiplimab-rwlc and its use in cancer treatment.
Ceritinib (brand name: Zykadia) is a targeted therapy medication used in the treatment of a specific type of non-small cell lung cancer (NSCLC) that harbors certain genetic mutations.
Ceritinib is classified as a tyrosine kinase inhibitor (TKI) and specifically targets anaplastic lymphoma kinase (ALK) gene rearrangements. These gene rearrangements lead to the overexpression of the ALK protein, which promotes the growth and survival of cancer cells in a subset of NSCLC cases.
Ceritinib works by inhibiting the activity of the abnormal ALK protein. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Ceritinib is indicated for:
Common side effects of ceritinib may include nausea, vomiting, diarrhea, fatigue, and elevated liver enzyme levels. As with any medication, ceritinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on ceritinib and its use in NSCLC treatment.
Cetuximab (brand name: Erbitux) is a targeted therapy medication used in the treatment of certain types of cancer, particularly colorectal cancer and head and neck cancer.
Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), a protein that plays a role in regulating cell growth and survival. Overexpression of EGFR is common in some types of cancer and can contribute to uncontrolled cell growth and tumor progression.
Cetuximab works by binding to the EGFR protein on the surface of cancer cells, preventing its activation and signaling. This helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Cetuximab is indicated for the following:
Common side effects of cetuximab may include skin rash, diarrhea, fatigue, nausea, and infusion-related reactions. As with any medication, cetuximab can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on cetuximab and its use in cancer treatment.
Cobimetinib fumarate (brand name: Cotellic) is a targeted therapy medication used in combination with other drugs for the treatment of specific types of cancer, particularly advanced melanoma.
Cobimetinib is classified as a MEK inhibitor, which means it targets and inhibits a protein called MEK (mitogen-activated protein kinase kinase). The MEK protein is a key component of the MAP kinase pathway, which plays a role in cell growth and division. Inhibition of the MEK pathway can slow down or inhibit the growth of cancer cells.
Cobimetinib is typically used in combination with a BRAF inhibitor, such as vemurafenib, for the treatment of advanced melanoma with a specific genetic mutation known as BRAF V600E or V600K. These mutations are found in a subset of melanoma cases and contribute to the growth of cancer cells.
The combination of cobimetinib and a BRAF inhibitor targets both the MAP kinase pathway and the BRAF protein, providing a more effective and comprehensive treatment approach.
Common side effects of cobimetinib fumarate may include rash, diarrhea, nausea, fatigue, and photosensitivity (increased sensitivity to sunlight). Like other targeted therapies, cobimetinib can also lead to more severe side effects, including potential effects on heart rhythm, liver function, and eye health.
As with any medication, it’s important to consult with a healthcare professional or refer to more recent sources for the latest information on cobimetinib fumarate and its use in cancer treatment.
Crenolanib is an investigational medication that belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). It is being developed for the treatment of specific types of cancer, particularly acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GISTs).
Crenolanib specifically targets and inhibits a mutant form of the FLT3 (FMS-like tyrosine kinase 3) receptor, which is commonly found in certain cases of AML and is associated with a poor prognosis. FLT3 mutations can lead to uncontrolled cell growth and survival in leukemia cells.
Crenolanib’s potential mechanism of action involves blocking the activity of the abnormal FLT3 protein, which could help slow down or inhibit the growth of leukemia cells and potentially improve patient outcomes.
In addition to AML, crenolanib has also shown promise in preclinical and early clinical studies for the treatment of GISTs, particularly those with specific genetic alterations.
It’s important to note that my knowledge is based on information available up until September 2021, and there may have been developments or changes since then. If you are seeking the most up-to-date information about crenolanib or any other medical treatment, I recommend consulting with a healthcare professional or referring to more recent sources like clinical trial databases and medical journals.
Crizotinib (brand name: Xalkori) is a targeted therapy medication used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and anaplastic lymphoma kinase (ALK)-positive advanced or metastatic NSCLC.
Crizotinib is classified as a tyrosine kinase inhibitor (TKI). It targets specific genetic alterations or mutations, such as the ALK gene rearrangement and ROS1 gene rearrangement, which are found in a subset of NSCLC cases.
The ALK and ROS1 gene rearrangements lead to the overexpression of abnormal proteins that drive the growth and survival of cancer cells. Crizotinib works by inhibiting the activity of these abnormal proteins, slowing down or inhibiting the growth of cancer cells and leading to tumor shrinkage and improved patient outcomes.
Crizotinib is indicated for the following:
Common side effects of crizotinib may include fatigue, diarrhea, nausea, vomiting, and edema (fluid retention). As with any medication, crizotinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on crizotinib and its use in cancer treatment.
Docetaxel (brand name: Taxotere) is a chemotherapy medication used in the treatment of various types of cancer, including breast cancer, lung cancer, prostate cancer, and other malignancies.
Docetaxel is classified as a taxane-class chemotherapy drug. It works by interfering with microtubule function during cell division, ultimately leading to cell death. Microtubules are essential for cell division, and by disrupting their normal function, docetaxel inhibits the growth and division of cancer cells.
Docetaxel is indicated for the treatment of different cancer types, including:
Docetaxel is typically administered intravenously. Common side effects may include neutropenia (low white blood cell count), anemia, fatigue, hair loss, nausea, and fluid retention.
As with any chemotherapy medication, docetaxel can have potential interactions and side effects, which should be discussed with a healthcare provider. It’s important to work closely with a healthcare team and follow their recommendations while taking docetaxel or any other cancer treatment.
Entrectinib (brand name: Rozlytrek) is a targeted therapy medication used in the treatment of certain types of cancer, particularly solid tumors that have specific genetic alterations.
Entrectinib is classified as a tyrosine kinase inhibitor (TKI) and specifically targets neurotrophic tyrosine receptor kinase (NTRK) genes, as well as anaplastic lymphoma kinase (ALK) and ROS1 gene rearrangements. These genetic alterations can lead to the overexpression of abnormal proteins that drive the growth and survival of cancer cells.
Entrectinib works by inhibiting the activity of these abnormal proteins. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Entrectinib is indicated for the treatment of:
Common side effects of entrectinib may include fatigue, nausea, dizziness, diarrhea, and increased liver enzyme levels. As with any medication, entrectinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on entrectinib and its use in cancer treatment.
Erdafitinib (brand name: Balversa) is a targeted therapy medication used for the treatment of a specific type of bladder cancer known as metastatic or locally advanced urothelial carcinoma with fibroblast growth factor receptor (FGFR) genetic alterations.
Erdafitinib is classified as an FGFR inhibitor and specifically targets certain mutations in the FGFR gene. These mutations can lead to the overactivation of FGFR proteins, which can contribute to the growth and survival of cancer cells.
Erdafitinib works by inhibiting the activity of the abnormal FGFR proteins. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has an FGFR3 or FGFR2 alteration and has progressed during or after prior platinum-containing chemotherapy.
Common side effects of erdafitinib may include fatigue, increased phosphate levels, diarrhea, nails separating from the nailbed (onycholysis), and dry mouth. As with any medication, erdafitinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on erdafitinib and its use in bladder cancer treatment.
As of my last knowledge update in September 2021, “futibatinib” doesn’t appear to be a recognized medication or treatment option. It’s possible that the term is misspelled or not yet widely known or established in medical literature up to that point.
If you have a specific question about a medication or treatment, I recommend providing more context or verifying the name to ensure accurate information. If “futibatinib” is a new or experimental drug that has emerged after my last update, I recommend consulting with a healthcare professional or referring to more recent sources such as clinical trial databases, medical journals, or official drug regulatory websites for the most up-to-date information.
Gilteritinib fumarate (brand name: Xospata) is a targeted therapy medication used for the treatment of certain types of acute myeloid leukemia (AML) with specific genetic mutations.
Gilteritinib is classified as a tyrosine kinase inhibitor (TKI) and specifically targets the FLT3 (FMS-like tyrosine kinase 3) receptor, which is commonly mutated in some cases of AML. These mutations can lead to the overactivation of the FLT3 protein, contributing to the growth and survival of cancer cells.
Gilteritinib works by inhibiting the activity of the abnormal FLT3 protein. By doing so, it helps to slow down or inhibit the growth of leukemia cells and can lead to improved patient outcomes.
Gilteritinib fumarate is indicated for the treatment of adult patients with relapsed or refractory FLT3 mutation-positive AML.
Common side effects of gilteritinib may include fatigue, nausea, diarrhea, elevated liver enzyme levels, and musculoskeletal pain. As with any medication, gilteritinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on gilteritinib fumarate and its use in AML treatment.
Ibrutinib (brand name: Imbruvica) is a targeted therapy medication used for the treatment of certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and marginal zone lymphoma (MZL).
Ibrutinib is classified as a Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in the survival and proliferation of B-cells, which are a type of white blood cell involved in the immune system. Mutations or overactivity of BTK can contribute to the development of various blood cancers.
Ibrutinib works by inhibiting the activity of BTK, thereby disrupting the signaling pathways that promote the growth and survival of cancer cells. This leads to the inhibition of cancer cell growth and improved patient outcomes.
Ibrutinib is indicated for the following:
Common side effects of ibrutinib may include bleeding, bruising, diarrhea, fatigue, nausea, and muscle pain. As with any medication, ibrutinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on ibrutinib and its use in blood cancer treatment.
Ivosidenib (brand name: Tibsovo) is a targeted therapy medication used for the treatment of a specific type of acute myeloid leukemia (AML) with a specific genetic mutation.
Ivosidenib is classified as an isocitrate dehydrogenase-1 (IDH1) inhibitor. Mutations in the IDH1 gene can lead to the production of abnormal forms of the IDH1 enzyme, which contribute to the development of AML. Ivosidenib works by targeting and inhibiting these mutant forms of the IDH1 enzyme. By doing so, it helps to restore normal cellular function and promote differentiation of leukemia cells, leading to improved patient outcomes.
Ivosidenib is indicated for the treatment of adult patients with newly diagnosed AML who have an IDH1 mutation and are not eligible for intensive chemotherapy, as well as for the treatment of adult patients with relapsed or refractory AML with an IDH1 mutation.
Common side effects of ivosidenib may include fatigue, nausea, vomiting, diarrhea, and differentiation syndrome (a serious side effect associated with rapid cell maturation). As with any medication, ivosidenib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on ivosidenib and its use in AML treatment.
Letrozole (brand name: Femara) is a hormonal therapy medication used primarily in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women.
Letrozole is classified as an aromatase inhibitor. Aromatase is an enzyme responsible for converting androgens (male hormones) into estrogen (female hormone) in postmenopausal women. In hormone receptor-positive breast cancer, the growth of cancer cells is often influenced by estrogen. Letrozole works by inhibiting the activity of aromatase, which leads to a reduction in estrogen levels in the body. Lower estrogen levels help slow down or inhibit the growth of hormone-sensitive cancer cells.
Letrozole is indicated for:
Common side effects of letrozole may include hot flashes, fatigue, joint pain, nausea, and bone loss. As with any medication, letrozole can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on letrozole and its use in breast cancer treatment.
Neratinib maleate (brand name: Nerlynx) is a targeted therapy medication used for the treatment of certain types of breast cancer, particularly HER2-positive early-stage breast cancer.
Neratinib is classified as a tyrosine kinase inhibitor (TKI) and specifically targets human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some breast cancers. HER2-positive breast cancers tend to be more aggressive, and targeted therapies like neratinib aim to inhibit the growth and survival of cancer cells by blocking HER2 signaling.
Neratinib maleate is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer who have been previously treated with trastuzumab-based therapy. Extended adjuvant treatment refers to treatment given after initial therapy (such as surgery and adjuvant trastuzumab) to further reduce the risk of cancer recurrence.
Common side effects of neratinib may include diarrhea, nausea, vomiting, fatigue, and decreased appetite. As with any medication, neratinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on neratinib maleate and its use in breast cancer treatment.
Nilotinib (brand name: Tasigna) is a targeted therapy medication used for the treatment of certain types of blood cancers, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Nilotinib is classified as a tyrosine kinase inhibitor (TKI) and specifically targets the BCR-ABL protein, which is a fusion protein created by the Philadelphia chromosome abnormality. The BCR-ABL protein drives the growth and survival of cancer cells in CML and Ph+ ALL.
Nilotinib works by inhibiting the activity of the abnormal BCR-ABL protein. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to a reduction in disease progression and improved patient outcomes.
Nilotinib is indicated for the treatment of:
Common side effects of nilotinib may include fatigue, nausea, diarrhea, rash, and low blood cell counts. As with any medication, nilotinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on nilotinib and its use in blood cancer treatment.
Olaparib (brand name: Lynparza) is a targeted therapy medication used for the treatment of certain types of cancer, particularly ovarian cancer, breast cancer, and prostate cancer.
Olaparib is classified as a poly(ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in repairing damaged DNA within cells. In cancer cells with deficiencies in DNA repair mechanisms, such as those with mutations in the BRCA genes, inhibiting PARP can lead to the accumulation of DNA damage and cell death.
Olaparib is indicated for the treatment of:
Common side effects of olaparib may include fatigue, nausea, vomiting, anemia, and decreased appetite. As with any medication, olaparib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on olaparib and its use in cancer treatment.
Olutasidenib (brand name: Tibsovo) is a targeted therapy medication used for the treatment of a specific type of acute myeloid leukemia (AML) with a specific genetic mutation.
Olutasidenib is classified as an isocitrate dehydrogenase-1 (IDH1) inhibitor. Mutations in the IDH1 gene can lead to the production of abnormal forms of the IDH1 enzyme, which contribute to the development of AML. Olutasidenib works by targeting and inhibiting these mutant forms of the IDH1 enzyme. By doing so, it helps to restore normal cellular function and promote differentiation of leukemia cells, leading to improved patient outcomes.
Olutasidenib is indicated for the treatment of adult patients with newly diagnosed AML who have an IDH1 mutation and are not eligible for intensive chemotherapy, as well as for the treatment of adult patients with relapsed or refractory AML with an IDH1 mutation.
Common side effects of olutasidenib may include fatigue, nausea, diarrhea, differentiation syndrome (a serious side effect associated with rapid cell maturation), and increased levels of certain liver enzymes. As with any medication, olutasidenib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on olutasidenib and its use in AML treatment.
Osimertinib mesylate (brand name: Tagrisso) is a targeted therapy medication used for the treatment of a specific type of non-small cell lung cancer (NSCLC) with specific genetic mutations.
Osimertinib is classified as a tyrosine kinase inhibitor (TKI) and specifically targets epidermal growth factor receptor (EGFR) mutations, particularly T790M mutations. These mutations are associated with a subset of NSCLC cases and can drive the growth and survival of cancer cells.
Osimertinib works by inhibiting the activity of the abnormal EGFR protein with T790M mutations. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Osimertinib mesylate is indicated for the treatment of:
Common side effects of osimertinib may include diarrhea, skin rash, dry skin, fatigue, and nail problems. As with any medication, osimertinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on osimertinib mesylate and its use in NSCLC treatment.
Pembrolizumab (brand name: Keytruda) is an immunotherapy medication used for the treatment of certain types of cancer.
Pembrolizumab is classified as a programmed cell death protein 1 (PD-1) inhibitor. PD-1 is a protein found on the surface of certain immune cells, and it plays a role in regulating the immune response. Some cancer cells can exploit the PD-1 pathway to evade detection by the immune system. Pembrolizumab blocks the PD-1 pathway, allowing the immune system to recognize and attack cancer cells more effectively.
Pembrolizumab is indicated for the treatment of various types of cancer, including:
Common side effects of pembrolizumab may include fatigue, nausea, decreased appetite, diarrhea, and skin rash. Immune-related side effects can also occur due to the activation of the immune system. As with any medication, pembrolizumab can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on pembrolizumab and its use in cancer treatment.
Pralsetinib (brand name: Gavreto) is a targeted therapy medication used for the treatment of a specific type of non-small cell lung cancer (NSCLC) and thyroid cancer.
Pralsetinib is classified as a tyrosine kinase inhibitor (TKI) that targets rearranged during transfection (RET) gene alterations, including RET fusions and mutations. RET gene alterations can drive the growth and spread of cancer cells.
Pralsetinib works by inhibiting the activity of the abnormal RET protein resulting from these genetic alterations. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Pralsetinib is indicated for the treatment of:
Common side effects of pralsetinib may include fatigue, constipation, musculoskeletal pain, and hypertension (high blood pressure). As with any medication, pralsetinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on pralsetinib and its use in cancer treatment.
Regorafenib (brand name: Stivarga) is a targeted therapy medication used for the treatment of certain types of cancer, particularly colorectal cancer and gastrointestinal stromal tumors (GISTs).
Regorafenib is classified as a multikinase inhibitor that targets multiple protein kinases involved in tumor growth and angiogenesis (formation of new blood vessels). It acts against several kinases, including those that are part of the VEGFR, PDGFR, and RAF/MEK/ERK signaling pathways.
Regorafenib works by inhibiting the activity of these kinases, which helps to slow down or inhibit the growth of cancer cells and can also impact tumor blood supply.
Regorafenib is indicated for the treatment of:
Common side effects of regorafenib may include fatigue, hand-foot skin reaction (palmar-plantar erythrodysesthesia), diarrhea, hypertension (high blood pressure), and decreased appetite. As with any medication, regorafenib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on regorafenib and its use in cancer treatment.
Ribociclib (brand name: Kisqali) is a targeted therapy medication used for the treatment of certain types of breast cancer.
Ribociclib is classified as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4 and CDK6 are proteins that regulate the cell cycle and play a role in promoting cell division. In hormone receptor-positive breast cancer, the growth of cancer cells is often influenced by the activity of CDK4 and CDK6. Ribociclib works by inhibiting the activity of these proteins, which helps to slow down or inhibit the growth of cancer cells.
Ribociclib is indicated for the treatment of:
Common side effects of ribociclib may include fatigue, nausea, diarrhea, decreased appetite, and low blood cell counts. As with any medication, ribociclib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on ribociclib and its use in breast cancer treatment.
Ruxolitinib phosphate (brand names: Jakafi, Jakavi) is a targeted therapy medication primarily used for the treatment of certain types of myeloproliferative neoplasms, particularly myelofibrosis and polycythemia vera.
Ruxolitinib is classified as a Janus kinase (JAK) inhibitor. Janus kinases are enzymes that play a role in transmitting signals involved in cell growth and immune function. In myeloproliferative neoplasms, there is dysregulation of these signaling pathways, leading to abnormal cell proliferation.
Ruxolitinib works by inhibiting the activity of JAK1 and JAK2 enzymes, which helps to reduce the signaling that drives the abnormal growth of blood cells in conditions like myelofibrosis and polycythemia vera.
Ruxolitinib phosphate is indicated for the treatment of:
Common side effects of ruxolitinib may include anemia, thrombocytopenia, fatigue, and gastrointestinal symptoms. As with any medication, ruxolitinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on ruxolitinib phosphate and its use in myeloproliferative neoplasms treatment.
Sonidegib (brand name: Odomzo) is a targeted therapy medication used for the treatment of a specific type of skin cancer called basal cell carcinoma (BCC). It is particularly used for advanced basal cell carcinoma that is locally advanced and cannot be treated with surgery or radiation.
Sonidegib is classified as a hedgehog pathway inhibitor. The hedgehog signaling pathway plays a role in regulating cell growth and differentiation during development, but when abnormally activated, it can contribute to the growth of basal cell carcinoma.
Sonidegib works by inhibiting a component of the hedgehog pathway called smoothened (SMO), which helps to slow down or inhibit the growth of cancer cells in basal cell carcinoma.
Sonidegib is indicated for the treatment of:
Common side effects of sonidegib may include muscle spasms, hair loss, fatigue, nausea, and loss of taste. As with any medication, sonidegib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on sonidegib and its use in basal cell carcinoma treatment.
Sorafenib tosylate (brand name: Nexavar) is a targeted therapy medication used for the treatment of certain types of cancer, primarily kidney cancer (renal cell carcinoma) and liver cancer (hepatocellular carcinoma), as well as certain types of thyroid cancer.
Sorafenib is classified as a multikinase inhibitor. It targets several kinases, including those involved in angiogenesis (formation of new blood vessels) and cell growth, which are processes often dysregulated in cancer.
Sorafenib works by inhibiting the activity of these kinases, thereby helping to slow down or inhibit the growth of cancer cells and reducing the blood supply to tumors.
Sorafenib tosylate is indicated for the treatment of:
Common side effects of sorafenib may include fatigue, diarrhea, hand-foot skin reaction (palmar-plantar erythrodysesthesia), rash, and hypertension (high blood pressure). As with any medication, sorafenib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on sorafenib tosylate and its use in cancer treatment.
Talazoparib tosylate (brand name: Talzenna) is a targeted therapy medication used for the treatment of a specific type of breast cancer with specific genetic mutations.
Talazoparib is classified as a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme involved in repairing DNA damage in cells. In cancer cells with defects in DNA repair pathways, inhibiting PARP can lead to the accumulation of DNA damage and ultimately cell death.
Talazoparib works by inhibiting the activity of PARP enzymes, particularly in cancer cells that have mutations in BRCA1 and BRCA2 genes (associated with DNA repair). By doing so, it targets the vulnerabilities of cancer cells with these mutations.
Talazoparib tosylate is indicated for the treatment of:
Common side effects of talazoparib may include fatigue, anemia, nausea, and decreased appetite. As with any medication, talazoparib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on talazoparib tosylate and its use in breast cancer treatment.
Temsirolimus (brand name: Torisel) is a targeted therapy medication used for the treatment of certain types of cancer.
Temsirolimus is classified as a mammalian target of rapamycin (mTOR) inhibitor. The mTOR pathway is involved in regulating cell growth, proliferation, and survival. Dysregulation of this pathway can contribute to cancer development and progression.
Temsirolimus works by inhibiting the activity of mTOR, which helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Temsirolimus is indicated for the treatment of:
Common side effects of temsirolimus may include fatigue, rash, mucositis, diarrhea, and decreased appetite. As with any medication, temsirolimus can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on temsirolimus and its use in cancer treatment.
Tepotinib hydrochloride (brand name: Tepmetko) is a targeted therapy medication used for the treatment of a specific type of non-small cell lung cancer (NSCLC) with a specific genetic alteration.
Tepotinib is classified as a mesenchymal-epithelial transition (MET) inhibitor. MET is a receptor tyrosine kinase that plays a role in cell growth, survival, and migration. Abnormalities in the MET pathway, such as MET exon 14 skipping mutations, can contribute to the development and progression of certain cancers, including NSCLC.
Tepotinib works by inhibiting the activity of the abnormal MET protein resulting from these genetic alterations. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Tepotinib hydrochloride is indicated for the treatment of:
Common side effects of tepotinib may include peripheral edema (swelling), nausea, diarrhea, fatigue, and elevated liver enzymes. As with any medication, tepotinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on tepotinib hydrochloride and its use in NSCLC treatment.
Tipifarnib (brand name: Zokinvy) is a targeted therapy medication used for the treatment of a specific type of hematologic malignancy called chronic myelomonocytic leukemia (CMML) with a specific genetic mutation.
Tipifarnib is classified as a farnesyltransferase inhibitor. Farnesyltransferase is an enzyme involved in a process called protein prenylation, which plays a role in regulating the function of certain proteins involved in cell growth and survival. In CMML, mutations in the gene called HRAS can lead to abnormal activation of signaling pathways that contribute to cancer development.
Tipifarnib works by inhibiting the activity of farnesyltransferase, which helps to interfere with the signaling pathways driven by HRAS mutations. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to improved patient outcomes.
Tipifarnib is indicated for the treatment of:
Common side effects of tipifarnib may include fatigue, nausea, vomiting, diarrhea, and decreased appetite. As with any medication, tipifarnib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on tipifarnib and its use in CMML treatment.
Trametinib dimethyl sulfoxide (brand name: Mekinist) is a targeted therapy medication used for the treatment of certain types of cancer, particularly melanoma and certain forms of non-small cell lung cancer (NSCLC).
Trametinib is classified as a mitogen-activated protein kinase (MEK) inhibitor. The MEK pathway is involved in cell growth and proliferation, and mutations in this pathway can contribute to cancer development.
Trametinib works by inhibiting the activity of the MEK enzymes, which helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Trametinib dimethyl sulfoxide is indicated for the treatment of:
Common side effects of trametinib may include rash, diarrhea, peripheral edema (swelling), and hypertension (high blood pressure). As with any medication, trametinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on trametinib dimethyl sulfoxide and its use in cancer treatment.
Tucatinib (brand name: Tukysa) is a targeted therapy medication used for the treatment of a specific type of breast cancer known as HER2-positive metastatic breast cancer.
HER2 (human epidermal growth factor receptor 2) is a protein that can be overexpressed in certain breast cancers, leading to more aggressive tumor growth. Tucatinib is designed to target and inhibit HER2, thereby disrupting the signaling pathways that promote cancer cell growth.
Tucatinib is classified as a tyrosine kinase inhibitor (TKI). It works by selectively inhibiting the activity of the HER2 kinase, which is a component of the HER2 signaling pathway. By inhibiting HER2 kinase activity, tucatinib helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Tucatinib is indicated for the treatment of:
Common side effects of tucatinib may include diarrhea, nausea, vomiting, fatigue, and hand-foot syndrome (palmar-plantar erythrodysesthesia). As with any medication, tucatinib can have potential interactions and side effects, which should be discussed with a healthcare provider.
Please note that medical knowledge and treatments may have advanced since my last update. It’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on tucatinib and its use in breast cancer treatment.
Vemurafenib (brand name: Zelboraf) is a targeted therapy medication used for the treatment of certain types of cancer, particularly melanoma with a specific genetic mutation.
Vemurafenib is classified as a BRAF inhibitor. BRAF is a protein kinase involved in the MAP kinase signaling pathway, which plays a role in cell growth, proliferation, and survival. Mutations in the BRAF gene, particularly the V600E mutation, can lead to the dysregulation of this pathway and contribute to the development of certain cancers.
Vemurafenib works by inhibiting the activity of the abnormal BRAF protein resulting from the V600E mutation. By doing so, it helps to slow down or inhibit the growth of cancer cells and can lead to tumor shrinkage and improved patient outcomes.
Vemurafenib is indicated for the treatment of:
Common side effects of vemurafenib may include rash, photosensitivity, fatigue, arthralgia (joint pain), and cutaneous squamous cell carcinoma (a type of skin cancer). As with any medication, vemurafenib can have potential interactions and side effects, which should be discussed with a healthcare provider.
It’s important to note that medical knowledge and treatments can evolve, so it’s recommended to consult with a healthcare professional or refer to more recent sources for the latest information on vemurafenib and its use in cancer treatment.
Plot No. 28, 29, Electronic City, Phase IV, Udyog Vihar, Sector 18, Gurugram, Haryana 122001, India
© Copyright 2023 Dr.AV Cancer Institute. All right reserved
